Anika Therapeutics develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair. The Company is committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. 
Anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care and skin rejuvenation. The Company's proprietary technology is based on hyaluronic acid, a naturally occurring polymer found throughout the body vital for proper joint health and tissue function. Its products include MONOVISC®, ORTHOVISC®, and ORTHOVISC® mini used in the treatment of osteoarthritis; HYVISC® used in the treatment of equine osteoarthritis; ELEVESS® cosmetic dermal filler with lidocaine; ANIKAVISC® viscoelastic for ophthalmic surgery; INCERT®-S anti-adhesion surgical gel; and next generation products for joint health, advanced wound care and other applications.
At Anika, they believe that an individual’s feelings about their age are driven by perceptions about the state of their body.
Show more
Type
Public
HQ
Bedford, US
Founded
1992
Size (employees)
122 (est)
Anika Therapeutics was founded in 1992 and is headquartered in Bedford, US
Report incorrect company information

Key People/Management at Anika Therapeutics

Joseph Darling

Joseph Darling

Chief Executive Officer

Anika Therapeutics Office Locations

Anika Therapeutics has offices in Ponte Fabbrica and Bedford
Bedford, US (HQ)
32 Wiggins Ave
Ponte Fabbrica, IT
3 Via Ponte della Fabbrica
Show all (2)
Report incorrect company information

Anika Therapeutics Financials and Metrics

Anika Therapeutics Financials

Anika Therapeutics's revenue was reported to be $113.42 m in FY, 2017
USD

Revenue (Q1, 2018)

21.3 m

Net income (Q1, 2018)

(6.7 m)

EBIT (Q1, 2018)

(7.8 m)

Market capitalization (25-May-2018)

594.4 m

Closing share price (25-May-2018)

40.3

Cash (31-Mar-2018)

141.8 m
Anika Therapeutics's current market capitalization is $594.4 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

75.1 m105.6 m93 m103.4 m113.4 m

Revenue growth, %

41%(12%)11%

Cost of goods sold

22.8 m20.9 m21.1 m24 m

Gross profit

52.3 m84.7 m71.9 m79.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

17.8 m34 m26.3 m22.1 m15.5 m22.9 m23.7 m22.3 m26.6 m25.8 m23.4 m33.5 m27.2 m21.3 m

General and administrative expense

5 m4.8 m

R&D expense

4.4 m5.8 m

Operating expense total

10 m10.1 m11.1 m11.8 m10 m10.5 m10.5 m11.6 m13.1 m12.1 m15.4 m15.7 m16.9 m29.1 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

63.3 m100.2 m110.7 m104.3 m133.3 m

Inventories

11 m12.4 m14.9 m16 m22 m

Current Assets

94.6 m139 m176.4 m170.4 m206.3 m

PP&E

52.4 m53.6 m40.1 m52.3 m56.2 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

64.1 m82.2 m84.9 m71.8 m99.8 m103.9 m108.5 m92.8 m89.1 m98 m119.4 m117.9 m127 m141.8 m

Inventories

11.6 m13 m13.9 m13.6 m12.5 m11.7 m12.1 m15.8 m17.3 m18 m16.2 m17.6 m20.3 m22.8 m

Current Assets

95 m113.5 m119.5 m128.7 m145.9 m155.7 m168.3 m147.9 m154.6 m161.1 m177.1 m192.9 m199 m208.2 m

PP&E

31.5 m33.8 m46.8 m49.2 m51.1 m51.6 m52.3 m54 m55.8 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

20.6 m38.3 m30.8 m32.5 m31.8 m

Depreciation and Amortization

4.8 m4.7 m3.8 m3.7 m4.3 m

Inventories

(2.8 m)(2 m)(2.9 m)(1.7 m)(6.5 m)

Accounts Payable

622.9 k(749.6 k)5.6 m(5.1 m)3.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

5 m15 m9.3 m6.2 m3.5 m7.8 m8.4 m6.9 m8.6 m9 m5.5 m(6.7 m)

Depreciation and Amortization

1.5 m

Inventories

13.9 m13.6 m12.5 m11.7 m12.1 m15.8 m17.3 m18 m16.2 m(3.9 m)

Accounts Payable

2.2 m1.2 m1.8 m1.7 m2.2 m3.3 m3.3 m1.9 m6.1 m(180 k)
USDY, 2018

Financial Leverage

1.1 x
Show all financial metrics

Anika Therapeutics Operating Metrics

FY, 2016

Patents (US)

21

Patents (foreign)

151

Patents Licensed

95

Patents Pending

14
Show all operating metrics
Report incorrect company information